Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Heart Failure Drugs Companies

Heart failure is a medical condition characterized by the heart's inability to pump blood effectively, leading to a range of symptoms and complications. Various pharmaceutical companies are involved in the development and production of drugs used in the management and treatment of heart failure. These drugs aim to alleviate symptoms, improve cardiac function, and reduce the risk of adverse events.

Heart Failure Drugs Key Companies*Disclaimer: List of key companies in no particular orderLatest Heart failure Companies Update

May 2023: The U.S. Food and medicine Administration has greenlighted a medicine developed by Lexicon Pharmaceuticals Inc to treat heart failure in a wide range of patients, including adults with type 2 diabetes. Sotagliflozin, marketed under the trade name Inpefa, is the company's first FDA-approved oral medication. As an adjunct to insulin treatment for type 1 diabetes, it has previously been rejected for clearance in the United States. Inhibiting SGLT1 and SGLT2 proteins, which sotagliflozin does, helps manage blood glucose levels and reduces the risk of weight gain. The drug is scheduled to be released by Lexicon at the end of June, and the company has stated that the wholesale pricing will be comparable to other branded heart failure drugs.

July 2023: The Drugs Controller General of India gave AstraZeneca Pharma India permission to import Dapagliflozin tablets for the treatment of heart failure in July 2023. According to a regulatory document, the pharmaceutical business has been granted approval by the DCGI to import pharmaceutical formulations of a new medicine for sale. It went on to say that dapagliflozin capsules and tablets should be used to treat adult heart failure. This approval clears the way for the product to be marketed in India for the designated use, pending the acquisition of any necessary government permits.

Janaury 2023: Tablets with a combination of sacubitril and valsartan, intended for use in the treatment of heart disease, were released by Glenmark Pharmaceuticals in India in January 2023. Sacu V is a cutting-edge, cost-effective medication that has been found to relieve symptoms related to heart failure with reduced ejection fraction (HFrEF) and minimize the risk of cardiovascular mortality or hospitalization. According to the manufacturer, a doctor's prescription is required for both daily doses of Sacu V. Its FDA-approved use is for treating individuals with chronic heart failure and HFrEF to lessen the likelihood of cardiovascular-related deaths and hospitalizations.List of Heart failure Key companies in the market

  • Amgen Inc. (US)

  • AstraZeneca (UK)

  • Novartis AG (Switzerland)

  • Boehringer Ingelheim International GmbH (Germany)

  • Johnson & Johnson Services

  • Bristol-Myers Squibb Company (US)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.